Compass Pathways outlines potential 30- to 60-day FDA review target as it plans to complete COMP360 NDA in next 2 weeks

COMPASS Pathways nears COMP360 NDA filing for TRD, with potential 30-60 day FDA review and 2027 launch prep.

CryptoAlerta — análise de criptomoedas e mercado em tempo real